Salinomycin induces selective cytotoxicity to MCF-7 mammosphere cells through targeting the Hedgehog signaling

Ying-Zi Fu1, Yuan-Yuan Yan1, Miao He1

  • 1Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, Liaoning 110122, P.R. China.

Oncology Reports
|January 1, 2016
PubMed

Insights

Salinomycin selectively kills breast cancer stem cells by inhibiting the Hedgehog signaling pathway. This pathway is crucial for cancer stem cell maintenance and survival, making it a potential therapeutic target.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Breast cancer stem cells (BCSCs) drive tumor chemoresistance, recurrence, and metastasis.
  • Salinomycin (SAL) shows selective inhibition of BCSCs, but its mechanism is unclear.
  • The Hedgehog (Hh) signaling pathway is implicated in cancer stem cell maintenance and carcinogenesis.

Purpose of the Study:

  • To investigate if Salinomycin induces cytotoxicity in BCSCs by targeting the Hh signaling pathway.
  • To elucidate the molecular mechanisms of SAL's action on BCSCs.

Main Methods:

  • Enrichment of breast CSCs using MCF-7 mammospheres (MCF-7 MS) exhibiting BCSC properties.
  • Assessment of SAL's selective cytotoxicity on MCF-7 MS cells.
  • Analysis of Hh pathway activation and downstream targets in response to SAL treatment.

Main Results:

  • MCF-7 MS cells displayed typical BCSC characteristics and activated Hh signaling.
  • SAL selectively reduced MCF-7 MS cell viability.
  • SAL inhibited Hh pathway activation by downregulating PTCH, SMO, Gli1, and Gli2, and their downstream targets (C-myc, Bcl-2, Snail).
  • Shh-induced Hh signaling partially reversed SAL's effects.

Conclusions:

  • SAL-induced cytotoxicity in BCSCs is linked to the inhibition of Hh signaling.
  • The Hh pathway is a critical factor in BCSC pathogenesis and a potential therapeutic target for breast cancer treatment.